<DOC>
	<DOCNO>NCT00577993</DOCNO>
	<brief_summary>The goal clinical research study compare chemotherapy give rituximab chemotherapy follow rituximab . The safety treatment schedule study . Laboratory test genetic change blood bone marrow study also monitor .</brief_summary>
	<brief_title>Fludarabine , Mitoxantrone , Dexamethasone ( FND ) Plus Rituximab Lymphoma Patients</brief_title>
	<detailed_description>Rituximab monoclonal antibody design attach leukemia cell activate series event may cause cancer cell die . Fludarabine design make cancer cell less able repair damage DNA ( genetic material cell ) . This may increase likelihood cell die . Mitoxantrone design stop cancer cell make DNA , may stop cell make cell . Dexamethasone corticosteroid similar natural hormone make body . Dexamethasone often give MM patient combination chemotherapy treat cancer . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group . Each group receive 8 `` cycle '' treatment . One ( 1 ) cycle last 28 day . Group 1 : If Group 1 , receive follow drug follow time . Each study cycle 28 day : - Rituximab give needle vein 90 minute Days 1 8 first course Cycle 1 , Day 1 Cycles 2-5 Fludarabine/ Mitoxantrone/ Dexamethasone ( FND ) treatment . - Fludarabine give needle vein 15 minute Days 2-4 cycle . - Mitoxantrone give needle vein 15 minute Day 2 cycle . - You take dexamethasone mouth water Days 1-5 28-day cycle ( FND ) . If miss dos study drug , please contact research staff instruction . You receive rituximab Cycles 6-8 . When 8 cycle finish , begin receive drug interferon Days 1-14 month 1 year . Dexamethasone give Days 1-3 every month 1 year . Patients group 2 receive fludarabine Days 1-3 , mitoxantrone Day 1 , dexamethasone Days 1-5 28-day cycle . When 8 cycle treatment finish , patient begin receive drug interferon Days 1-14 month 1 year . Dexamethasone give Days 1-3 every month 1 year . About 4 month interferon treatment start , patient group 2 begin receive rituximab month 6 month . Other drug may give help decrease risk ease side effect . Treatment may delay stop side effect severe . Most drug give vein . A catheter ( tube ) place vein decrease number needle stick . Dexamethasone may take mouth instead give vein . Some patient study , change certain gene receive different chemotherapy drug patient study . The patient , like patient , receive rituximab interferon . But instead FND chemotherapy regimen , receive sequence three regimen , CHOD-Bleo , ESHAP , NOPP . The drug regimens include : cyclophosphamide , doxorubicin , vincristine , bleomycin , VP-16 , Ara-C , cisplatin , mitoxantrone , procarbazine , corticosteroid ( prednisone , methylprednisolone , dexamethasone ) . During study , patient blood test every week . Complete exam give Cycles 2 4 ; patient return clinic . Every 2 3 cycle , patient chest x-ray CT scan abdomen pelvis . Bone marrow sample take . Heart function test ( EKG ) do need . After study end , patient return checkup every 3 month first year , every 4 month year 2 3 , every 6 month year 4 5 . After , checkup need year . Blood bone marrow sample take visit . This investigational study . Rituximab approve FDA commercial use . The drug use study also approve commercial use . About 210 patient take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Previously untreated stage IV indolent Bcell lymphoma [ Amendment May 2001 : eligibility restrict follicular lymphoma ] 2 . Age &lt; 76</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Indolent Lymphoma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Novantrone</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Anti-CD20</keyword>
	<keyword>IDEC-C2B8</keyword>
	<keyword>Chimeric Anti-CD20 Antibody</keyword>
	<keyword>Interferon</keyword>
	<keyword>Interferon Alpha-2b</keyword>
	<keyword>IFN</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Methyl-Prednisolone</keyword>
	<keyword>Procarbazine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>FND</keyword>
</DOC>